Medicxi Ventures Management (Jersey) Ltd

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed July 16, 2024), Medicxi Ventures Management (Jersey) Ltd reported 4 stock positions worth $335.3 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 53.8% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 22.9%) and Newamsterdam Pharma (NAMS, 16.4%). Compared with Q1 2024, it sold out of 1. The biggest sale was an exit from Merus (MRUS).

Most Recent 13F
Q2 2026
Location
ST. HELIER, Y9
CIK
0001715579
Portfolio Value
$335.3M (Q2 2024)
SEC Filing
0000950123-24-006607 ↗ filed Jul 16, 2024

Holdings Value

0$200.0M$400.0M$600.0M$800.0M$1.0B Q1 2024: $449.2M Q1 2024 Q2 2024: $335.3M $335.3M Q2 2024 Q3 2024: $528.9M Q3 2024 Q4 2024: $529.0M Q4 2024 Q1 2025: $437.7M Q1 2025 Q2 2025: $427.3M Q2 2025 Q3 2025: $744.4M Q3 2025 Q4 2025: $835.0M Q4 2025 Q1 2026: $981.8M Q1 2026 Q2 2026: $177.4M Q2 2026

Holdings 4 stocks · $335.3M
CNTA Centessa Pharmaceuticals Ltd. 53.77% 19,963,157 $180.3M No change
PHAT Phathom Pharmaceuticals Inc. 22.93% 7,464,572 $76.9M No change
NAMS Newamsterdam Pharma Co. NV 16.44% 2,869,565 $55.1M No change
AURA Aura Biosciences Inc. 6.85% 3,039,892 $23.0M No change

Portfolio Sells Q1 2024 → Q2 2024
MRUS Merus NV Sold out 0.00% −11.72

Portfolio Buys Q1 2024 → Q2 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.4MPHAT, NAMS, AURA
Q1 2026 4$981.8MCNTA, NAMS, PHAT, AURA
Q4 2025 5$835.0MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q3 2025 5$744.4MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q2 2025 5$427.3MCNTA, PHAT, NAMS, RAPT, AURA
Q1 2025 5$437.7MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q4 2024 5$529.0MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q3 2024 4$528.9MCNTA, PHAT, NAMS, AURA
Q2 2024 4$335.3MCNTA, PHAT, NAMS, AURA
Q1 2024 5$449.2MCNTA, PHAT, NAMS, MRUS, AURA